Canaccord Genuity reiterates a 'Buy/Best Idea' on Heartware...

Canaccord Genuity reiterates a 'Buy/Best Idea' on Heartware Int'l (NASDAQ: HTWR), PT $98.

Canaccord analyst says, "HeartWare completed a $125M convertible transaction (excluding overallotments), which we think gives HTWR adequate capital to 1) begin a robust build-out of its US sales and support infrastructure (most of the spending will occur in H2/11E) and 2) expand the next-generation MVAD pipeline (HTWR may seek to develop more than one version, in our estimation). We reiterate our rating and $98 target, and would be accumulating shares on the recent pullback."